Skip to main content
Premium Trial:

Request an Annual Quote

N.C. Startup Will Provide Affy Gene Chip Services For Duke

NEW YORK, March 7 - Durham, NC-based startup Expression Analysis will provide gene chip processing services for the Duke University Medical Center, the company said on Thursday.

 

Expression Analysis will provide statistical analysis and laboratory services for Duke researchers using Affymetrix microarrays. The company will process and hybridize Duke's RNA samples and also undertake target-probe development.

 

Financial details of the arrangement were not disclosed.

 

This agreement will be overseen by Holly Dressman, who directs the microarray facility at Duke University Medical Center. The project director is EA chief of genomic sciences Laura Reid, who was previously director of the microarray facility at the University of North Carolina in Chapel Hill.

 

EA has close ties to Duke: three of its scientific advisory board members are Duke researchers, and the company's chief operating officer, Steven Casey, was formerly a Howard Hughes administrator at Duke.

 

Casey said in a statement that this outsourcing arrangement will allow Duke to reduce overhead. The company hopes to become a primary service providers for Affymetrix products, and offer low-cost gene chip analysis to academics, biotech companies and government researchers.

 

Expression Analysis was launched earlier this year by Analytical Sciences, a Durham contract research organization.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.